The Key To HIV: Gilead Sciences, To Develop Drugs For HIV And NASH, Details Inside
With HIV being considered as one of the long dreaded diseases, experts have yet found the appropriate solution to the problem. Until recently, as Gilead Sciences Inc. (GILD) CEO John Milligan started his presentation at the 35th annual J.P. Morgan Healthcare Conference in San Francisco, together with the investors of the said biopharmaceutical company, it was revealed that they will be starting to launch a project that aims to put emphasis on Hepatitis C, NASH and HIV. Authorities have also revealed that the company will be spending as much as $31.6 billion to show their support in putting an end to these diseases.
Gilead Sciences, To Develop Drugs For HIV And NASH
According to reports revealed by Drug Discovery And Development, the money that will be spent will allegedly be used to support 12 new HIV cure research projects. The series of projects are said to be initiated by the country's leading academic institutions, non-profit organizations and community groups from across the globe, which focuses on three key areas namely, translational research, efficacy studies in animal models and community perspectives of HIV cure. Executive Vice President, Research, Gilead Sciences William Lee, PhD, said that considering their experience gained throughout the years in addressing the issue of HIV/AIDS, they highlighted the fact that there is no one-size-fits-all solution. However, it was found that the company is in fact, excited about the potential of these projects and is looking forward to seeing the results and all the learnings that will be incorporated to it.
Meanwhile, as per Investopedia, Milligan is reportedly optimistic about Gilead's HIV product portfolio. However, the current HIV drugs which are making good revenues for Gilead are based on tenofovir disoproxil fumarate (TDF) medication, which Milligan believes is dying out. In line with it, it was found that the company will now be switching its focus into alternative tenofovir alafenamide (TAF)-based HIV drugs, which include Genvoya, Descovey, and Odefsey drugs. Ultimately, authorities from the said company have highly emphasized that they were recently announced as one of the foremost corporate providers of philanthropic support to address HIV/AIDS by the Funders Concerned About AIDS (FCAA) organization.
This DIY HIV Testing Kits Might Just Save You Before The Problem Gets Worse, Find Out How
Considering that HIV cases are already perceived to be on the rise, how does this new type of DIY testing kits be of help? How does it differ from the usual type testing that we know? Is this even accurate? Here’s what health experts have to say
Find Out London’s Secret To A Massive HIV Decline: Could This Be The ‘Cure’?
With the ever growing cases of HIV, a significant number of experts believe that the definite cure is yet to be discovered. But, what is London’s secret to a dramatic decline of HIV cases? Could this over the counter drug be the perfect solution all along? Here’s what health authorities have to say
HIV Spread Because Of Cosmetic Procedure Is Now Being Investigated: Are Cosmetics Not Safe Anymore? Details Inside
With the growing evidence of how HIV can be transmitted, how can a certain cosmetic product be an agent of HIV transmission? Does it imply that cosmetic products are also not safe? Here's what health experts have to say
MORE IN ITECHPOST
Top 6 Smartphones Packed With Qualcomm's Snapdragon 821 Chipset
The Xiaomi Mi Mix features a 6.4-inch IPS LCD touchscreen with a screen resolution of 1080 x 2040 pixels. It runs on Android 6.0 (upgradable to Android 7.0 Nougat) and is packed with a Snapdragon 821 chipset.
Update On The Health Of Former President Bush; Breathing Tubes Indicate Pneumonia
Doctors in Houston Hospital are evaluating the health status of former President George H.W. Bush before deciding to remove his breathing tube.